INDIANAPOLIS, Dec. 11, 2017 /PRNewswire/ -- Eli Lilly and
Company (NYSE: LLY) today announced that Kimberly Blackwell, M.D., one of the nation's
leading breast cancer researchers, will join Lilly Oncology as vice
president of early phase development and immuno-oncology on
March 12, 2018.
Dr. Blackwell is currently professor of medicine and assistant
professor of radiation oncology at Duke
University Medical Center. She also serves as the
co-director of the Duke women's cancer
program, associate director for strategic relations for the Duke
Cancer Institute, research scholar for Susan G. Komen, and senior strategist for the
Duke Innovation and Entrepreneurship Program. She will report to
Levi Garraway, M.D., Ph.D., senior
vice president, Global Development & Medical Affairs of Lilly
Oncology.
"We are pleased and honored to welcome Dr. Blackwell to Lilly,"
said Sue Mahony, Ph.D., senior vice
president and president of Lilly Oncology. "She is highly regarded
for her leadership in cancer research, especially metastatic breast
cancer, where she has led programs that resulted in numerous
groundbreaking regulatory approvals in the oncology sector."
"Furthermore, she has been on the forefront of research in
oncology vaccines, immuno-oncology and biosimilars, giving her the
unique expertise that will be pivotal in helping us continue to
develop and advance novel treatments for people living with
cancer."
About Kimberly Blackwell,
M.D.
A graduate of Mayo Clinic Medical School, Dr.
Blackwell is professor of medicine and assistant professor of
radiation oncology at Duke University
Medical Center. She has played a major role in developing therapies
that represent revolutionary non-chemotherapy based approaches for
treating breast cancer. Her clinical and research interests include
various topics in breast cancer including endocrine therapy, novel
HER2 therapies, breast cancer vaccines, and other experimental
therapeutics.
She has studied and served as the principal investigator on
studies that led to regulatory approval of four cancer agents,
including the first biosimilar treatment for cancer in the United States. Due to her leadership, she
has received numerous awards, including the Duke University Distinguished Alumni in 2015 and
TIME Magazine's 100 Most Influential People in the World in
2013.
Additionally, Dr. Blackwell is a recipient of the Young
Investigator Award in breast cancer from the National Cancer
Institute Specialized Program of Research Excellence and the
Joseph Greenfield Award for
Mentorship of Clinical Research.
About Lilly Oncology
For more than 50
years, Lilly has been dedicated to delivering life-changing
medicines and support to people living with cancer and those who
care for them. Lilly is determined to build on this heritage and
continue making life better for all those affected by cancer around
the world. To learn more about Lilly's commitment to people with
cancer, please visit www.LillyOncology.com.
About Eli Lilly and Company
Lilly is a global
healthcare leader that unites caring with discovery to make life
better for people around the world. We were founded more than a
century ago by a man committed to creating high-quality medicines
that meet real needs, and today we remain true to that mission in
all our work. Across the globe, Lilly employees work to discover
and bring life-changing medicines to those who need them, improve
the understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us at www.lilly.com and
newsroom.lilly.com/social-channels.
C-LLY
Refer to: Carole Copeland;
carole_copeland@lilly.com; (317) 610-6196
View original content with
multimedia:http://www.prnewswire.com/news-releases/kimberly-blackwell-md-to-become-vice-president-of-early-phase-development-and-immuno-oncology-at-lilly-oncology-300569350.html
SOURCE Eli Lilly and Company